
Please try another search
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.
Name | Age | Since | Title |
---|---|---|---|
David M. Peereboom | - | - | Scientific Advisory Board Member |
Daniel Levin | - | - | Scientific Advisory Board Member |
Ming Fu Chiang | - | 2023 | Scientific Advisory Board Member |
Keithly A. Garnett | 49 | 2023 | CFO & Director |
Axel H. Schonthal | - | - | Scientific Advisory Board Member |
Amir Farrokh Heshmatpour | 57 | 2023 | Executive Chairman & Secretary |
Thomas C. Chen | 60 | 2023 | Founder, CEO, Chief Scientific Officer & Chairman |
Steven L. Gianotta | - | - | Scientific Advisory Board Member |
Bader Almonawer | - | 2025 | Director |
Jimmy J. Delshad | 85 | 2025 | Independent Director |
Victoria Husted Medvec | 61 | 2025 | Independent Director |
Ishwar K. Puri | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review